{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:51:44Z","timestamp":1793022704155,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005609","name":"University of Turku","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To prospectively compare the ability of <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT and whole-body MRI (WBMRI) with DWI to detect prostate cancer (PCa) lesions and assess their local stage. Additionally, to evaluate the correlation between PSMA uptake on PET\/CT and PSMA expression as assessed by immunohistochemistry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Men with newly diagnosed unfavourable intermediate or high-risk PCa underwent <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT and WBMRI with DWI before robot-assisted laparoscopic prostatectomy. Diagnostic accuracy for intraprostatic tumour localization, seminal vesicle invasion (SVI), and extraprostatic extension (EPE) was evaluated using whole-mount prostatectomy specimens as the reference standard. SUVmax was compared with immunohistochemical PSMA staining intensity quantified using QuPath software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET\/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET\/CT and 74.0\u201384.0% for MRI, whereas those of non-index lesions were 70.0\u201375.0% for PET\/CT and 20.0\u201365.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET\/CT and 0.648\u20130.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman\u2019s \u03c1\u2009=\u20090.427, <jats:italic>p<\/jats:italic>\u2009=\u20090.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>\n              <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT demonstrated high sensitivity in localizing intraprostatic carcinoma lesions but seemed inferior to WBMRI in detecting EPE. PSMA uptake appears to depend on both PSMA expression and lesion size. These findings highlight the complementary roles of PET\/CT and MRI in the detection and tumor staging of PCa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>Clinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07208-z","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:20:11Z","timestamp":1743484811000},"page":"3709-3719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective comparison of 18F-PSMA-1007 PET\/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6642-9608","authenticated-orcid":false,"given":"Aino","family":"Kivikallio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-8978","authenticated-orcid":false,"given":"Simona","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6457-9339","authenticated-orcid":false,"given":"Irena","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7177","authenticated-orcid":false,"given":"Mikael","family":"Anttinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-3570","authenticated-orcid":false,"given":"Ivan","family":"Jambor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-1715","authenticated-orcid":false,"given":"Janne","family":"Verho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9390-1198","authenticated-orcid":false,"given":"Jukka","family":"Kemppainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu J.","family":"Aronen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-0015","authenticated-orcid":false,"given":"Peter J.","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-4602","authenticated-orcid":false,"given":"Otto","family":"Ettala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-4604","authenticated-orcid":false,"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"7208_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics. 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/CAAC.21660","DOI":"10.3322\/CAAC.21660"},{"key":"7208_CR2","doi-asserted-by":"publisher","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"7208_CR3","doi-asserted-by":"publisher","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet. 2020. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7","DOI":"10.1016\/s0140-6736(20)30314-7"},{"key":"7208_CR4","doi-asserted-by":"publisher","unstructured":"Gossili F, Mogensen AW, Konnerup TC, Bouchelouche K, Alberts I, Afshar-Oromieh A, et al. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/S00259-023-06392-0","DOI":"10.1007\/S00259-023-06392-0"},{"key":"7208_CR5","doi-asserted-by":"publisher","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023. https:\/\/doi.org\/10.1016\/J.EURURO.2023.03.001","DOI":"10.1016\/J.EURURO.2023.03.001"},{"issue":"1","key":"7208_CR6","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7208_CR7","doi-asserted-by":"publisher","unstructured":"Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/S41598-018-22594-1","DOI":"10.1038\/S41598-018-22594-1"},{"key":"7208_CR8","unstructured":"Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357\u201362."},{"key":"7208_CR9","doi-asserted-by":"publisher","unstructured":"Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, et al. Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/S00259-021-05296-1","DOI":"10.1007\/S00259-021-05296-1"},{"key":"7208_CR10","doi-asserted-by":"publisher","unstructured":"Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol. 2021. https:\/\/doi.org\/10.1016\/J.EUO.2020.06.012","DOI":"10.1016\/J.EUO.2020.06.012"},{"key":"7208_CR11","doi-asserted-by":"publisher","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017. https:\/\/doi.org\/10.1016\/J.EURURO.2016.08.003","DOI":"10.1016\/J.EURURO.2016.08.003"},{"key":"7208_CR12","doi-asserted-by":"publisher","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/ SNMM procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/S00259-022-06089-W","DOI":"10.1007\/S00259-022-06089-W"},{"key":"7208_CR13","doi-asserted-by":"publisher","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020. https:\/\/doi.org\/10.1097\/PAS.0000000000001497","DOI":"10.1097\/PAS.0000000000001497"},{"key":"7208_CR14","doi-asserted-by":"publisher","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/S41598-017-17204-5","DOI":"10.1038\/S41598-017-17204-5"},{"key":"7208_CR15","doi-asserted-by":"publisher","unstructured":"Schned AR, Wheeler KJ, Hodorowski CA, Heaney JA, Ernstoff MS, Amdur RJ, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol. 1996. https:\/\/doi.org\/10.1097\/00000478-199612000-00009","DOI":"10.1097\/00000478-199612000-00009"},{"key":"7208_CR16","doi-asserted-by":"publisher","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/JNUMED.119.234187","DOI":"10.2967\/JNUMED.119.234187"},{"key":"7208_CR17","doi-asserted-by":"publisher","unstructured":"Luo L, Zheng A, Chang R, Li Y, Gao J, Wang Z, et al. Evaluating the value of 18F-PSMA-1007 PET\/CT in the detection and identification of prostate cancer using histopathology as the standard. Cancer Imaging. 2023. https:\/\/doi.org\/10.1186\/S40644-023-00627-X","DOI":"10.1186\/S40644-023-00627-X"},{"key":"7208_CR18","doi-asserted-by":"publisher","unstructured":"Mookerji N, Pfanner T, Hui A, Huang G, Albers P, Mittal R, et al. Fluorine-18 prostate-specific membrane Antigen\u20131007 PET\/CT vs multiparametric MRI for locoregional staging of prostate cancer. JAMA Oncol. 2024. https:\/\/doi.org\/10.1001\/JAMAONCOL.2024.3196","DOI":"10.1001\/JAMAONCOL.2024.3196"},{"key":"7208_CR19","doi-asserted-by":"publisher","unstructured":"Tr\u00e4g\u00e5rdh E, Simoulis A, Bjartell A, J\u00f6gi J. Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/JNUMED.121.261993","DOI":"10.2967\/JNUMED.121.261993"},{"key":"7208_CR20","doi-asserted-by":"publisher","unstructured":"Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, et al. Intraindividual comparison of 18F-PSMA-1007 PET\/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/JNUMED.116.189233","DOI":"10.2967\/JNUMED.116.189233"},{"key":"7208_CR21","doi-asserted-by":"publisher","unstructured":"Exterkate L, Hermsen R, K\u00fcsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, et al. Head-to-head comparison of 18F-PSMA-1007 positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging with whole-mount histopathology as reference in localisation and staging of primary prostate cancer. Eur Urol Oncol. 2023. https:\/\/doi.org\/10.1016\/J.EUO.2023.04.006","DOI":"10.1016\/J.EUO.2023.04.006"},{"key":"7208_CR22","doi-asserted-by":"publisher","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/JNUMED.121.263448","DOI":"10.2967\/JNUMED.121.263448"},{"key":"7208_CR23","doi-asserted-by":"publisher","unstructured":"Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, et al. Reproducibility and accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/JNUMED.123.266164","DOI":"10.2967\/JNUMED.123.266164"},{"key":"7208_CR24","doi-asserted-by":"publisher","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Schilham MGM, Muselaers CHJ, Z\u00e1mecnik P, Mulders PFA, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2021. https:\/\/doi.org\/10.1038\/S41391-020-00292-2","DOI":"10.1038\/S41391-020-00292-2"},{"key":"7208_CR25","doi-asserted-by":"publisher","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/JNUMED.117.195172","DOI":"10.2967\/JNUMED.117.195172"},{"key":"7208_CR26","doi-asserted-by":"publisher","unstructured":"Heetman JG, Hermsen R, Exterkate L, K\u00fcsters-Vandevelde HVN, Brouwer LJM, Somford DM, et al. Immunohistochemical and histopathological validation of 18F-PSMA-1007 PET\/CT for intraprostatic cancerous lesions. Prostate. 2023. https:\/\/doi.org\/10.1002\/PROS.24595","DOI":"10.1002\/PROS.24595"},{"key":"7208_CR27","doi-asserted-by":"publisher","unstructured":"Cytawa W, Kircher S, K\u00fcbler H, Werner RA, Weber S, Hartrampf P, et al. Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET\/CT scans? Immunohistochemical validation in 40 surgical specimens. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/S00259-022-05831-8","DOI":"10.1007\/S00259-022-05831-8"},{"key":"7208_CR28","doi-asserted-by":"publisher","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/S00259-021-05501-1","DOI":"10.1007\/S00259-021-05501-1"},{"key":"7208_CR29","doi-asserted-by":"publisher","unstructured":"Al Jalali V, Wasinger G, Rasul S, Grubm\u00fcller B, Wulkersdorfer B, Balber T, et al. Consecutive prostate-specific membrane antigen (PSMA) and antigen receptor (AR) PET imaging shows positive correlation with AR and PSMA protein expression in primary hormone-na\u00efve prostate cancer. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/JNUMED.122.264981","DOI":"10.2967\/JNUMED.122.264981"},{"key":"7208_CR30","doi-asserted-by":"publisher","unstructured":"Patel KR, van der Heide UA, Kerkmeijer LGW, Schoots IG, Turkbey B, Citrin DE, et al. Target volume optimization for localized prostate cancer. Pract Radiat Oncol. 2024. https:\/\/doi.org\/10.1016\/J.PRRO.2024.06.006","DOI":"10.1016\/J.PRRO.2024.06.006"},{"key":"7208_CR31","doi-asserted-by":"publisher","unstructured":"Spohn SKB, Kramer M, Kiefer S, Bronsert P, Sigle A, Schultze-Seemann W, et al. Comparison of manual and Semi-Automatic [18F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/FONC.2020.600690","DOI":"10.3389\/FONC.2020.600690"},{"key":"7208_CR32","doi-asserted-by":"publisher","unstructured":"Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, et al. Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/S00259-020-05059-4","DOI":"10.1007\/S00259-020-05059-4"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07208-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:08:10Z","timestamp":1754356090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07208-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7208"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07208-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Hospital District of Southwest Finland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}